Amedicheck Drug Screen THC, COC, OPI, AMP, MET, PCP, MDMA, BAR, BZ
510(k) K080872
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK080872 | Date19 Aug 2008 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- LDJ
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3870
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
The Amedicheck Drug Screen is an enzyme immunoassay device designed for the qualitative detection of multiple drug metabolites in human urine specimens. It employs a multi-panel test format to simultaneously identify THC, cocaine (COC), opioids (OPI), amphetamines (AMP), methamphetamine (MET), phencyclidine (PCP), benzodiazepines (BZ), barbiturates (BAR), and MDMA at specified cutoff concentrations. This lateral flow immunoassay provides a visual readout for rapid, point-of-care screening applications.
The device is intended for professional use in clinical toxicology settings and is supplied as a single-use, non-sterile test kit. It requires no special storage conditions and is classified as a Class II medical device under FDA regulations (K080872). The test is performed by adding a urine specimen to the test cup, with results visible within minutes. No regulatory approval beyond the FDA 510(k) clearance is stated in the specifications.
Other devices from Amedica Biotech, Inc.
Questions
AI-generated answers, 19 Sep 2026
What types of drugs can the Amedicheck Drug Screen detect in a urine sample?
The Amedicheck Drug Screen is designed to qualitatively detect metabolites of nine different drug classes in human urine: THC (cannabinoids), cocaine (COC), opioids (OPI), amphetamines (AMP), methamphetamine (MET), phencyclidine (PCP), benzodiazepines (BZ), barbiturates (BAR), and MDMA. It uses a multi-panel enzyme immunoassay format to simultaneously screen for these substances at specified cutoff concentrations.
How is the Amedicheck Drug Screen supplied, and is it intended for single-use?
The Amedicheck Drug Screen is supplied as a single-use, non-sterile test kit. Each kit is intended for one-time use in a clinical toxicology setting, where a urine specimen is added to the test cup to produce a visual result within minutes. This design ensures no risk of cross-contamination between patients.
What kind of storage conditions are required for the Amedicheck Drug Screen?
The device does not require any special storage conditions, such as refrigeration or controlled humidity. It can be stored at room temperature, making it convenient for point-of-care use in clinical settings where refrigeration may not always be available.
How long does it take to get results from the Amedicheck Drug Screen?
The Amedicheck Drug Screen provides results within minutes of adding the urine specimen to the test cup. This rapid turnaround is ideal for immediate screening in clinical toxicology settings, allowing for quick decision-making.
What is the regulatory pathway for the Amedicheck Drug Screen, and how was it classified?
The Amedicheck Drug Screen received FDA clearance through a 510(k) submission, specifically classified as a Class II medical device under the FDA’s regulations. The device was determined to be substantially equivalent to a predicate product and was reviewed by the Clinical Toxicology Advisory Committee. The product code assigned is LDJ, and it falls under the regulation number 862.3870.